Business Context and Reporting Period
This Form 8-K Current Report was filed by Silexion Therapeutics Corp on July 16, 2025. The registrant is a Cayman Islands exempted company with principal executive offices in Ramat-Gan, Israel. The report details a corporate action regarding the company's capital structure.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on a corporate governance event.
Material Changes
The primary material change announced is a prospective 1-for-15 reverse share split of all issued and outstanding ordinary shares, as well as authorized but unissued shares. Key details include:
- Par Value Adjustment: The par value per ordinary share will increase from $0.0009 to $0.0135.
- Fractional Shares: No fractional shares will be issued; fractional entitlements for DTC participants will be rounded up to the nearest whole number.
- Effectiveness: The split becomes effective after market close on July 28, 2025.
- Trading Resumption: Shares will begin trading on a reverse split-adjusted basis on the Nasdaq Capital Market at the open on July 29, 2025.
- Ticker Symbol: The trading symbol will remain "SLXN."
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, management commentary on operational outlook, or specific risk factors beyond the standard implications of a reverse share split. The action is described as automatic, requiring no action from shareholders.
Investor Verification Checklist
- Verify the effective date of the reverse split (July 28, 2025, after market close).
- Confirm the adjusted trading start date (July 29, 2025, market open).
- Review the rounding policy for fractional shares (rounded up for DTC participants).
- Check the updated par value of $0.0135 per share.
- Confirm that the ticker symbol remains "SLXN" on the Nasdaq Capital Market.